Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find news

Free to read, “May need a subscription” and “Archived copy”: what they mean

Whether an article is free to read is a guess, not a test of your access. Each item is one of three:

  • No label: free to read (343 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
  • May need a subscription (16 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
  • “Free to read? Not known” (41 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.

Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 297 of 400 items have one.

FDA approves Auvelity to treat Alzheimer’s-related agitation

Alzheimer's News Today Drug approvals

The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. …

Read at Alzheimer's News Today →

FDA fast-tracks expanded home injections for Alzheimer’s drug Leqembi

Alzheimer's News Today Drug approvals

The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an approved treatment for early Alzheimer’s disease. …

Read at Alzheimer's News Today →

FDA decision on AXS-05 for Alzheimer’s agitation expected April 30

Alzheimer's News Today Drug approvals

The U.S. Food and Drug Administration (FDA) granted priority review to an application from Axsome Therapeutics seeking approval of its oral therapy AXS-05 to treat agitation related to Alzheimer’s disease, and expects to decide by April 30, the company said. …

Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet Archive

Last updated